Glioblastoma – Current Concepts, Prognostic Markers And Molecular Classification

Glioblastoma (GBM) has very poor prognosis despite aggressive therapy including surgical treatment. At present, few molecular markers could clarify GBM prognosis in greater detail. However, better understanding of the molecular pathogenesis would be the mainstay of improved, more personalized treatment modalities. Recent large-scale molecular studies brought new data that altered previous concepts about GBM; even molecular subtypes of GBM have been discovered. We discuss here the classic pathology of GBM along with molecular markers and subtypes of GBM as well as routine applications of these advances.